SCHEMBL717883

SCHEMBL717883

CC(NC(=O)O)c1cc2cccc(Br)c2nc1N1CCNC(=O)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.36
PRKCH P24723 1/20 0.34
PRKCE Q02156 1/20 0.34
GRIA1 P42261 3/20 0.34
PIN1 Q13526 1/20 0.34
KCNH2 Q12809 1/20 0.33
PIK3CD O00329 2/20 0.33
MAPT P10636 1/20 0.33
DPP4 P27487 1/20 0.32
PRMT5 O14744 1/20 0.32
PDE2A O00408 1/20 0.32
KDM4E B2RXH2 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31
ALDH1A1 P00352 2/20 0.31
WNT3A P56704 1/20 0.31
IKBKB O14920 1/20 0.31
OPRM1 P35372 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8072 0.89 SOS1 (0.36) SOS1PRKCHPRKCEGRIA1PIN1
SCHEMBL714566 0.84 PRKCH (0.37) SOS1PRKCHPRKCEGRIA1KCNH2
SCHEMBL714565 0.84 PRKCH (0.37) SOS1PRKCHPRKCEGRIA1KCNH2
SCHEMBL5299 0.83 SOS1 (0.38) SOS1PRKCHPRKCEGRIA1PIN1
SCHEMBL715233 0.81 SOS1 (0.36) SOS1PRKCHPRKCEKCNH2PIK3CD
SCHEMBL715234 0.81 SOS1 (0.36) SOS1PRKCHPRKCEKCNH2PIK3CD
SCHEMBL17530837 0.80 ADRA2A (0.34) PIK3CD
SCHEMBL715530 0.79 PIK3CD (0.39) SOS1PRKCHPRKCEPIN1PIK3CD
SCHEMBL715908 0.79 SOS1 (0.36) SOS1PRKCHPRKCEGRIA1DPP4
SCHEMBL718037 0.77 PDE4A (0.35) SOS1PRKCHPRKCEGRIA1PIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed
EP-2403847-A1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB Pharma, S.A. (BE) 2012-01-11 EP disclosed
WO-2010100405-A1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 SOS1 1414/4885PRKCH 396/4885PRKCE 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.